Testing for APOL1-mediated kidney disease (AMKD)

There is still much to learn about the APOL1 gene and its relationship to AMKD. By learning about patients’ APOL1 status, providers can better inform them of their AMKD risk. 

Knowing if your patient’s chronic kidney disease is due to APOL1 can provide patients with a clearer prognosis and help guide decisions about monitoring and effective treatment.

Identifying AMKD patients

Do you have patients who are experiencing a more rapid progression to kidney failure? Are some of your patients more resistant to steroid treatment?  

Making a definitive diagnosis and identifying the cause of CKD can help better inform patients of their status and guide decision-making.

Why test your patients?

Our Clinical Program Coordinator will help guide you through the setup and testing process.

Program is sponsored by Vertex Pharmaceuticals and is available at no cost* to eligible** patients.

*Vertex Pharmaceuticals is sponsoring this APOL1 Genotyping Program in collaboration with Labcorp, who will perform APOL1 genotyping and make genetic counseling available for eligible patients at no cost.

**Eligible patients are those of African ancestry who may self-identify as Black, African American, African, or Afro-Caribbean. Patients must have a diagnosis of chronic kidney disease, no history of kidney transplant, not have diabetes and must not be currently being treated with dialysis.

References: 1. Freedman BI, Burke W, Divers J, et al. Diagnosis, education, and care of patients with APOL1-associated nephropathy: a Delphi consensus and systematic review. J Am Soc Nephrol. 2021;32(7):1765-1778. doi:10.1681/ASN.2020101399 2. Beckerman P, Susztak K. APOL1: The Balance Imposed by Infection, Selection, and Kidney Disease. Trends Mol Med. 2018 Aug;24(8):682-695. doi: 10.1016/j.molmed.2018.05.008. Epub 2018 Jun 7. PMID: 29886044; PMCID: PMC6101980. 3. Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4):753-779. doi:10.1016/j.kint.2021.05.015